SIEMENS HEALTHINEERS AG

Siemens Healthineers keeps buying shares, launches FDA‑approved D‑Dimer 2.0, and partners for lab‑diagnostics growth—what this means for investors.

Discover how Siemens Healthineers blends AI‑driven imaging, resilient margins, and strategic reimbursement wins to stay a top player in German healthcare and DAX stability.

Siemens Healthineers boosts shares with a new AI‑driven radiotherapy platform and active buy‑back, positioning itself for growth amid rising interest rates and regulatory challenges.

Short‑selling of Siemens Healthineers reveals investor concern amid AI, cloud, and value‑based reimbursement shifts—discover how the company’s strategy and cost dynamics shape its future.

Short‑sale filings show AQR holding modest net short positions in Siemens Healthineers AG, hinting at market sentiment but not revealing operational details.

Siemens Healthineers shares dip 1.3% as markets stay cautious, yet its AI‑driven analyzers, multiplex immunoassays, and point‑of‑care tech keep the firm ahead in rapid, accurate diagnostics.

Siemens Healthineers partners with Novo to launch FDA‑cleared ELF blood test, enabling early, non‑invasive fibrosis detection for MASLD/MASH patients—cutting costs, boosting safety, and driving precision diagnostics.

Siemens Healthineers AG’s latest outlook cuts revenue growth but lifts earnings due to tariff refunds, while a diagnostics spin‑off aims to boost margins and focus AI‑enabled tech. Discover the key risks, balance‑sheet dynamics, and strategic shifts…

Siemens Healthineers expands its Atellica platform with capillary testing, adds AI‑driven diagnostics, and boosts sustainability—transforming in‑vitro diagnostics for faster, patient‑centric care.

Siemens Healthineers shares dip 1.25% as investors weigh Fed rate hike risk, yet AI‑driven imaging and strong EBIT margins position the company for long‑term growth.